New cocktail targets lung cancer in the brain: triple therapy shows promise in early trial
NCT ID NCT06812871
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This phase 2 study tested a combination of three drugs in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain and spinal cord (meningeal metastasis). The treatment included a high-dose targeted pill (furmonertinib), an intravenous drug that cuts off blood supply to tumors (bevacizumab), and chemotherapy injected directly into the spinal fluid (pemetrexed). The goal was to see if this triple approach could control the brain tumors longer and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- furmonertinib (a targeted cancer pill), bevacizumab (an anti-angiogenic drug), and pemetrexed (chemotherapy given into the spinal fluid)
- What this could lead to
- If this combination works, it could offer a new treatment option for lung cancer that has spread to the brain and spinal cord lining, potentially improving survival and quality of life.
- What could go wrong
- This is a small, single-arm phase 2 study with only 46 participants, so results may not apply to all patients. The combination also carries risks like bleeding, infection, and nerve damage from the spinal chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple-drug cocktail re-sensitize lung cancer to treatment?
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Should all advanced lung cancer patients get a brain scan? new trial aims to find out
- New hope for tough lung cancer? trial tests targeted drug against chemo
- New combo therapy for lung cancer under Real-World watch